Mr. Skvarka joined Trillium Therapeutics as its CEO and member of the Board of Directors in September 2019. He is an accomplished healthcare executive with 20 years of experience in the life sciences industry. Previously, Mr. Skvarka served as the President and CEO of Tal Medical, a Boston-based clinical-stage neuroscience company developing a potentially breakthrough neuromodulation treatment for depression discovered at McLean Hospital/Harvard University. Before Tal, he spent 14 years with Bain & Company, Boston, a global strategy consultancy, where for the last six years he was a leading partner in the Healthcare Practice. At Bain, Mr. Skvarka advised top pharmaceutical and biotech executives on complex issues spanning strategy, operational improvement and M&A, across a variety of therapeutic areas, including oncology, immunology, rare diseases and other. Prior to Bain, Mr. Skvarka was a Manager at Price Waterhouse Corporate Finance in London, UK and Vienna, Austria. Mr. Skvarka is a frequent speaker at conferences on topics related to healthcare. He holds a PhD degree in Economics from University of Economics, Slovakia, and an MBA from Harvard Business School.